title: Beta-interferons in multiple sclerosis: a single center experience in India.
abstract: BACKGROUND
  Indian-Asian multiple sclerosis behaves somewhat differently from Western disease. It is not known if the response to beta-interferon is also different.
  
  
  OBJECTIVE
  To demonstrate the decrease in relapses with beta-interferon in Indian patients with multiple sclerosis.
  
  
  METHODS
  Patients with relapsing-remitting or secondary progressive multiple sclerosis with at least two relapses were started on beta-interferon.
  
  
  RESULTS
  Sixteen patients were followed up for a period of 1-3 years. Fifteen had relapsing-remitting multiple sclerosis (MS). The mean number of relapses in these patients before interferons were started was 3.4. The mean yearly relapse rate was 1.3. The mean Kurtzke Expanded Disability Status Scale (EDSS) at the start of beta-interferon therapy in relapsing-remitting MS was 1.7. Ten of these patients were on Avonex((R)) (interferon beta1a) and six (including the patient with secondary progressive MS) were on Betaferon((R)) (interferon beta1b). On follow-up, three patients (two on Avonex((R)) and one on Betaferon((R)) ) had relapses. The respective beta-interferon being received by these patients was continued, with no further relapses. The remaining patients had no relapse or clinical or MRI progression after starting the drug. The side effect profile of the drug in these patients was favorable; although nearly all developed fever on the first day of the injection, only 50% of the patients continued to have fever after 3 months. Two patients developed psychiatric symptoms, requiring discontinuation of the drug.
  
  
  CONCLUSIONS
  Our prospective follow-up study shows that beta-interferons are safe and effective in Indian patients with relapsing-remitting or secondary progressive MS.
authors.affiliation: Department of Neurology, Command Hospital Air Force, Bangalore, India. chickusalil@yahoo.com
authors.forename: Salil
authors.initials: S
authors.lastname: Gupta
authors.forename: R
authors.initials: R
authors.lastname: Varadarajulu
authors.forename: R K
authors.initials: RK
authors.lastname: Ganjoo
references.citation: Neurology. 1993 Apr;43(4):655-61
references.pmid: 8469318
references.citation: J Assoc Physicians India. 1996 Nov;44(11):765-7
references.pmid: 9251448
references.citation: Neurology. 1996 Apr;46(4):907-11
references.pmid: 8780061
references.citation: J Neurol Sci. 1975 Oct;26(2):259-70
references.pmid: 1176993
references.citation: Neurology. 1996 Feb;46(2):385-7
references.pmid: 8614499
references.citation: Neurology. 1988 May;38(5):727-9
references.pmid: 3362370
references.citation: AJNR Am J Neuroradiol. 2000 Apr;21(4):702-6
references.pmid: 10782781
references.citation: Neurol India. 1999 Mar;47(1):8-11
references.pmid: 10339701
references.citation: Neurol India. 1999 Mar;47(1):12-7
references.pmid: 10339702
references.citation: Ann Neurol. 1995 Jan;37(1):7-15
references.pmid: 7529476
references.citation: Brain. 1997 Nov;120 ( Pt 11):2059-69
references.pmid: 9397021
references.citation: Acta Neurol Scand. 1980 Nov;62(5):312-21
references.pmid: 7468154
references.citation: J Neuroimmunol. 1999 Jan 1;93(1-2):8-14
references.pmid: 10378864
references.citation: Clin Immunol Immunopathol. 1996 Oct;81(1):1-11
references.pmid: 8808634
references.citation: Ann Acad Med Singap. 1985 Jan;14(1):32-6
references.pmid: 4004124
references.citation: Neurology. 1996 Jan;46(1):12-8
references.pmid: 8559358
references.citation: Neurol India. 1999 Mar;47(1):18-21
references.pmid: 10339703
references.citation: Neurology. 1999 Nov 10;53(8):1622-7
references.pmid: 10563602
references.citation: Neurology. 1983 Nov;33(11):1444-52
references.pmid: 6685237
references.citation: Ann Neurol. 2001 Jul;50(1):121-7
references.pmid: 11456302